摘要
原发性肝细胞癌(Hepatocellular Carcinoma, HCC)的发病率在全世界呈上升趋势,三氧化二砷(Arsenic trioxide, As2O3),作为一种中药单体,已经被大量用于HCC的实验及临床研究。但仍需要大样本的临床研究来明确其临床疗效,仍有必要进行As2O3联合TACE、化疗药物及靶向药物等治疗原发性肝癌的临床研究。
The incidence of Hepatocellular Carcinoma (HCC) is on the rise worldwide. Arsenic trioxide (As2O3), as a monomer of traditional Chinese medicine, has been widely used in experimental and clinical studies of HCC. However, large samples of clinical studies are still needed to clarify its clinical efficacy, and clinical studies on combination of As2O3 with TACE, chemotherapy drugs and targeted drugs for the treatment of primary liver cancer are still necessary.
出处
《中医学》
2020年第1期34-39,共6页
Traditional Chinese Medicine
基金
国家传染病重点项目(2012ZX10002-016)
中国国家自热科学基金(81102694)。
